According to the World Health Organization, 3.9% of the global population has had post-traumatic stress disorder (PTSD) at some stage in their lives. The PTSD incidence is approximately three times higher among people who are exposed to violent conflicts or war. Although the primary treatment is psychotherapy, the drug pipeline for PTSD treatment remains strong. Several companies are involved in research and development to conduct effective drugs, influencing the pipeline landscape significantly.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing post-traumatic stress disorder (PTSD) pipeline development activities are covered. Moreover, post-traumatic stress disorder (PTSD) collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
There are two types of post-traumatic stress disorder (PTSD) including acute stress disorder and complex PTSD (CPTSD). Acute stress disorder is a short-term mental health condition which can occur within the first month after experiencing a traumatic event. Complex PTSD is a mental health condition which can develop if a person experiences chronic trauma which includes long-term child physical or sexual abuse, long-term domestic violence and war among others.
The primary post-traumatic stress disorder (PTSD) treatment includes psychotherapy (talk therapy), especially forms of cognitive behavioral therapy (CBT). The specific forms of CBT include cognitive processing therapy, eye movement desensitization and reprocessing (EMDR) therapy, group therapy, prolonged exposure therapy and trauma-focused CBT. Currently, there are no medications approved by the Food and Drug Administration (FDA) for the treatment of post-traumatic stress disorder (PTSD). However, healthcare providers prescribe certain medications including antidepressants like selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs) and anti-anxiety medications.
Several pharma companies are developing innovative treatments to manage post-traumatic stress disorder (PTSD). There has been a significant growth in the treatment options for the condition. Positive results from clinical trials during the past decade of medication-assisted psychotherapy are providing hope to manage the disease effectively.
The PTSD drug pipeline includes a total of 466 drugs at various stages of development. Phase 2 holds the largest share, making up about 40% of the pipeline, followed by Phase 1 at 21%. Phase 3 accounts for 18%, while Phase 4 represents around 16%. Early Phase 1 makes up the smallest portion, with just 5%. This distribution shows a strong emphasis on mid-stage clinical research for PTSD treatments.
This product will be delivered within 3-5 business days.
Report Coverage
The Post-Traumatic Stress Disorder (PTSD) Drug Pipeline Report by the publisher gives comprehensive insights into ongoing post-traumatic stress disorder (PTSD) clinical trials. It covers various aspects related to the details of each of these drugs under development for post-traumatic stress disorder (PTSD). The report includes the analysis of over 100 pipeline drugs and 50+ companies. The post-traumatic stress disorder (PTSD) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from post-traumatic stress disorder (PTSD).The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing post-traumatic stress disorder (PTSD) pipeline development activities are covered. Moreover, post-traumatic stress disorder (PTSD) collaborations and commercial assessments are offered, helping stakeholders to make informed decisions.
Post-Traumatic Stress Disorder (PTSD) Drug Pipeline Outlook
Post-traumatic stress disorder (PTSD) is a mental health condition that develops after a traumatic event. The symptoms of this disorder involve anxiety, flashbacks, negative thoughts and beliefs, and hypervigilance among others. People who go through traumatic events may have temporary difficulty in adjusting and coping. Moreover, if the symptoms get worse and interfere with day-to-day functioning, it can develop into PTSD. The symptoms of PTSD may start within one month of a traumatic event. It can interfere with the ability to do normal daily tasks. Generally, post-traumatic stress disorder (PTSD) symptoms are grouped into four types, including, intrusive memories, negative changes in thinking and mood, avoidance, and changes in physical and emotional reactions.There are two types of post-traumatic stress disorder (PTSD) including acute stress disorder and complex PTSD (CPTSD). Acute stress disorder is a short-term mental health condition which can occur within the first month after experiencing a traumatic event. Complex PTSD is a mental health condition which can develop if a person experiences chronic trauma which includes long-term child physical or sexual abuse, long-term domestic violence and war among others.
The primary post-traumatic stress disorder (PTSD) treatment includes psychotherapy (talk therapy), especially forms of cognitive behavioral therapy (CBT). The specific forms of CBT include cognitive processing therapy, eye movement desensitization and reprocessing (EMDR) therapy, group therapy, prolonged exposure therapy and trauma-focused CBT. Currently, there are no medications approved by the Food and Drug Administration (FDA) for the treatment of post-traumatic stress disorder (PTSD). However, healthcare providers prescribe certain medications including antidepressants like selective serotonin reuptake inhibitors (SSRIs) or serotonin and norepinephrine reuptake inhibitors (SNRIs) and anti-anxiety medications.
Several pharma companies are developing innovative treatments to manage post-traumatic stress disorder (PTSD). There has been a significant growth in the treatment options for the condition. Positive results from clinical trials during the past decade of medication-assisted psychotherapy are providing hope to manage the disease effectively.
Post-Traumatic Stress Disorder (PTSD) Epidemiology
Around 3.9% of people worldwide are estimated to experience post-traumatic stress disorder (PTSD) at some point in their lives. However, this number rises sharply in individuals exposed to violent conflict or war, with rates reported to be as high as 15.3% - nearly three times higher than the global average. The risk is also significantly higher following experiences of sexual violence. In the general population, about 6 in every 100 adults are likely to develop PTSD during their lifetime, with women being twice as likely as men to be affected. Complex PTSD, a more severe form, is estimated to impact between 1% and 8% of people globally.Post-Traumatic Stress Disorder (PTSD) - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of post-traumatic stress disorder (PTSD) drug candidates based on several segmentations including:By Phase
The pipeline assessment report covers 50+ drug analyses based on phase.- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The post-traumatic stress disorder (PTSD) therapeutics assessment report covers 50+ drug analyses based on drug classes:
- Recombinant Fusion Proteins
- Small Molecule
- Monoclonal Antibody
- Peptide
- Polymer
- Gene Therapy
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.- Oral
- Parenteral
- Others
Post-Traumatic Stress Disorder (PTSD) - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for post-traumatic stress disorder (PTSD).The PTSD drug pipeline includes a total of 466 drugs at various stages of development. Phase 2 holds the largest share, making up about 40% of the pipeline, followed by Phase 1 at 21%. Phase 3 accounts for 18%, while Phase 4 represents around 16%. Early Phase 1 makes up the smallest portion, with just 5%. This distribution shows a strong emphasis on mid-stage clinical research for PTSD treatments.
Post-Traumatic Stress Disorder (PTSD) - Pipeline Assessment Segmentation, By Drug Classes
The drug molecules categories covered under post-traumatic stress disorder (PTSD) pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymer, and gene therapy. Currently under phase II, Jazz Pharmaceuticals is developing an investigational small molecule drug called JZP150 to treat post-traumatic stress disorder (PTSD) in adults. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for post-traumatic stress disorder (PTSD).Post-Traumatic Stress Disorder (PTSD) Clinical Trials Assessment - Competitive Dynamics
The post-traumatic stress disorder (PTSD) drug report insights involve the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in PTSD clinical trials:- Hoffmann-La Roche
- Synchroneuron Inc.
- Klarisana Physician Services PLLC
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Apollo Neuroscience, Inc.
- Palo Alto Health Sciences, Inc.
- Jazz Pharmaceuticals
- HealthTech Connex Inc.
- Boehringer Ingelheim
- GlaxoSmithKline
- Nobilis Therapeutics Inc.
- Others
Post-Traumatic Stress Disorder (PTSD) Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for post-traumatic stress disorder (PTSD). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of post-traumatic stress disorder (PTSD) drug candidates.Drug: Balovaptan
The trial is designed to evaluate the safety and effectiveness of administering 10 mg of balovaptan orally once a day in comparison to a similar placebo in adults with post-traumatic stress disorder (PTSD). The trial is sponsored by Hoffmann-La Roche and is currently under phase II.Drug: JZP150
The objective of the study is to assess the clinical safety and effectiveness of ZP150 in the treatment of adults with post-traumatic stress disorder (PTSD). The trial is sponsored by Jazz Pharmaceuticals and is currently under phase II.Drug: BI 1358894
Boehringer Ingelheim is developing this drug and is currently under phase II. The study is being conducted to find out whether the drug improves symptoms in post-traumatic stress disorder (PTSD) affected patients.Reasons To Buy This Report
The Post-Traumatic Stress Disorder (PTSD) Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for post-traumatic stress disorder (PTSD). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into post-traumatic stress disorder (PTSD) collaborations, regulatory environments, and potential growth opportunities within the treatment landscape.Key Questions Answered in the Post-Traumatic Stress Disorder (PTSD) - Pipeline Assessment Report
- Which companies/institutions are leading the post-traumatic stress disorder (PTSD) drug development?
- What is the efficacy and safety profile of post-traumatic stress disorder (PTSD) pipeline drugs?
- Which company is leading the post-traumatic stress disorder (PTSD) pipeline development activities?
- What is the current post-traumatic stress disorder (PTSD) commercial assessment?
- What are the opportunities and challenges present in the post-traumatic stress disorder (PTSD) drug pipeline landscape?
- What is the efficacy and safety profile of post-traumatic stress disorder (PTSD) pipeline drugs?
- Which company is conducting major trials for post-traumatic stress disorder (PTSD) drugs?
- Which companies/institutions are involved in post-traumatic stress disorder (PTSD) collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in post-traumatic stress disorder (PTSD)?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Post-Traumatic Stress Disorder (PTSD)
4 Patient Profile: Post-Traumatic Stress Disorder (PTSD)
5 Post-Traumatic Stress Disorder (PTSD): Epidemiology Snapshot
6 Post-Traumatic Stress Disorder (PTSD): Market Dynamics
7 Post-Traumatic Stress Disorder (PTSD): Key Facts Covered
8 Post-Traumatic Stress Disorder (PTSD), Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Post-Traumatic Stress Disorder (PTSD) Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Post-Traumatic Stress Disorder (PTSD) Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Post-Traumatic Stress Disorder (PTSD) Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Post-Traumatic Stress Disorder (PTSD) Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Post-Traumatic Stress Disorder (PTSD), Key Drug Pipeline Companies
